Soluble endoglin versus sFlt-1/PlGF ratio: detection of preeclampsia, HELLP syndrome, and FGR in a high-risk cohort
暂无分享,去创建一个
R. Kimmig | M. Darkwah Oppong | A. Gellhaus | A. Iannaccone | P. Mach | A. Köninger | B. Reisch | B. Schmidt | L. Mavarani | A. Köeninger
[1] C. Lees,et al. ISUOG Practice Guidelines: diagnosis and management of small-for-gestational-age fetus and fetal growth restriction. , 2020, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.
[2] A. Leaños-Miranda,et al. Soluble Endoglin As a Marker for Preeclampsia, Its Severity, and the Occurrence of Adverse Outcomes. , 2019, Hypertension.
[3] K. Nicolaides,et al. The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre‐eclampsia: A pragmatic guide for first‐trimester screening and prevention , 2019, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.
[4] S. Karumanchi,et al. Preeclampsia: Pathophysiology, Challenges, and Perspectives , 2019 .
[5] J. Gris,et al. Angiogenic factors for prediction of preeclampsia and intrauterine growth restriction onset in high-risk women: AngioPred study , 2019, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.
[6] L. Magee,et al. Hypertensive Disorders of Pregnancy: ISSHP Classification, Diagnosis, and Management Recommendations for International Practice. , 2018, Hypertension.
[7] L. Magee,et al. The hypertensive disorders of pregnancy: ISSHP classification, diagnosis & management recommendations for international practice. , 2018, Pregnancy hypertension.
[8] D. Charnock-Jones,et al. Screening for fetal growth restriction using fetal biometry combined with maternal biomarkers. , 2017, American journal of obstetrics and gynecology.
[9] A. Farr,et al. An sFlt-1:PlGF ratio of 655 is not a reliable cut-off value for predicting perinatal outcomes in women with preeclampsia. , 2018, Pregnancy hypertension.
[10] Nicola Persico,et al. Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia , 2017, The New England journal of medicine.
[11] E. Gratacós,et al. An integrated approach to fetal growth restriction. , 2017, Best practice & research. Clinical obstetrics & gynaecology.
[12] S. Brennecke,et al. Soluble fms-Like Tyrosine Kinase-1-to-Placental Growth Factor Ratio and Time to Delivery in Women With Suspected Preeclampsia , 2016, Obstetrics and gynecology.
[13] M. Bahloul,et al. [Up-to-date on the HELLP syndrome (Hemolysis, Elevated Liver enzymes and Low Platelets)]. , 2016, La Revue de medecine interne.
[14] A. Papageorghiou,et al. Consensus definition of fetal growth restriction: a Delphi procedure , 2016, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.
[15] S. Brennecke,et al. Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia. , 2016, The New England journal of medicine.
[16] K. Nicolaides,et al. Longitudinal changes in maternal soluble endoglin and angiopoietin‐2 in women at risk for pre‐eclampsia , 2014, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.
[17] K. Gomes,et al. Soluble Endoglin, Transforming Growth Factor-Beta 1 and Soluble Tumor Necrosis Factor Alpha Receptors in Different Clinical Manifestations of Preeclampsia , 2014, PloS one.
[18] H. Zeisler,et al. New Gestational Phase–Specific Cutoff Values for the Use of the Soluble fms-Like Tyrosine Kinase-1/Placental Growth Factor Ratio as a Diagnostic Test for Preeclampsia , 2014, Hypertension.
[19] O. Shaker,et al. Pathogenesis of preeclampsia , 2013, Human & experimental toxicology.
[20] K. Nicolaides,et al. Maternal Serum Soluble Endoglin at 30-33 Weeks in the Prediction of Preeclampsia , 2012, Fetal Diagnosis and Therapy.
[21] K. Lim,et al. Plasma Concentrations of Soluble Endoglin versus Standard Evaluation in Patients with Suspected Preeclampsia , 2012, PloS one.
[22] Kypros H. Nicolaides,et al. Competing Risks Model in Early Screening for Preeclampsia by Biophysical and Biochemical Markers , 2012, Fetal Diagnosis and Therapy.
[23] J. Oleszczuk,et al. Endoglin in pregnancy complicated by fetal intrauterine growth restriction in normotensive and preeclamptic pregnant women: a comparison between preeclamptic patients with appropriate-for-gestational-age weight infants and healthy pregnant women , 2012, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.
[24] K. Lim,et al. Angiogenic Factors and the Risk of Adverse Outcomes in Women With Suspected Preeclampsia , 2012, Circulation.
[25] L. Cordero,et al. Maternal Preeclampsia and Neonatal Outcomes , 2011, Journal of pregnancy.
[26] J. Dudenhausen,et al. An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia. , 2010, American journal of obstetrics and gynecology.
[27] Wenjiang J. Fu,et al. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate , 2008, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.
[28] B. Sibai,et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. , 2006, The New England journal of medicine.
[29] T. Libermann,et al. Soluble endoglin contributes to the pathogenesis of preeclampsia , 2006, Nature Medicine.
[30] I. Sargent,et al. Latest Advances in Understanding Preeclampsia , 2005, Science.
[31] J. López-Novoa,et al. Endoglin regulates nitric oxide‐dependent vasodilatation , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[32] K. Lim,et al. Circulating angiogenic factors and the risk of preeclampsia. , 2004, The New England journal of medicine.
[33] M. Letarte,et al. Primary structure of endoglin, an RGD-containing glycoprotein of human endothelial cells. , 1990, The Journal of biological chemistry.
[34] W. Youden,et al. Index for rating diagnostic tests , 1950, Cancer.